m+Medelevator.RU
← Поиск публикаций
Scientific reports · 2025

Titanium-prepared platelet-rich fibrin enhances alveolar ridge preservation: a randomized controlled clinical and radiographic study.

СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Aldommari Emad Aldden, Omair Ali, Qasem Tarek

Аннотация

This randomized controlled trial evaluated the efficacy of titanium-prepared platelet-rich fibrin (T-PRF) for alveolar ridge preservation (ARP) compared with leukocyte and platelet rich fibrin (L-PRF) and spontaneous healing. Thirty single-rooted teeth requiring extraction were randomly assigned to one of three groups (ARP with T-PRF, ARP with L-PRF, and spontaneous healing) using a flapless, atraumatic extraction approach. Radiographic measurements (bone width, height, and density) were obtained pre-operatively and at four months via OnDemand3D software, and clinical parameters-including post-operative pain, analgesic consumption, soft-tissue healing, periodontal probing depth, gingival recession, and keratinized tissue width-were assessed. At four months, the T-PRF group demonstrated substantially greater preservation of ridge dimensions (P = 0.000), and higher bone density (P = 0.000), along with improved soft-tissue healing (P < 0.05), lower pain scores (P = 0.000), and reduced analgesic use (P < 0.05). Periodontal parameters remained stable across the groups, except for keratinized tissue width (KTW), which was substantially greater in the T-PRF group (P = 0.020). There were substantial differences among the groups in the need for bone regeneration when implants were placed (P < 0.05). These findings support the clinical advantage of T-PRF in optimizing post-extraction outcomes for implant site development.This trial was registered in the UK's Clinical Study Registry ISRCTN (ISRCTN60191547).

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты